Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

Novo Nordisk’s share price fell on the news, trading 0.8% lower after being 4% higher earlier in the day. The shares are down 32% year-to-date and 59% from their all-time high. 4 ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he will continue as CEO for a while to smooth the leadership transition.

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's share price is down 54% from its peak in June 2024. Its U.S.-listed shares fell another 3% in premarket trading Friday. The company, headquartered in Bagsvaerd, ...

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug that made it onto the market outside the company's approved supply chain.